TY - JOUR
T1 - Epidemic and pandemic viral infections
T2 - Impact on tuberculosis and the lung
AU - Ong, Catherine Wei Min
AU - Migliori, Giovanni Battista
AU - Raviglione, Mario
AU - MacGregor-Skinner, Gavin
AU - Sotgiu, Giovanni
AU - Alffenaar, Jan Willem
AU - Tiberi, Simon
AU - Adlhoch, Cornelia
AU - Alonzi, Tonino
AU - Archuleta, Sophia
AU - Brusin, Sergio
AU - Cambau, Emmanuelle
AU - Capobianchi, Maria Rosaria
AU - Castilletti, Concetta
AU - Centis, Rosella
AU - Cirillo, Daniela M.
AU - D'Ambrosio, Lia
AU - Delogu, Giovanni
AU - Esposito, Susanna M.R.
AU - Figueroa, Jose
AU - Friedland, Jon S.
AU - Ho, Benjamin Choon Heng
AU - Ippolito, Giuseppe
AU - Jankovic, Mateja
AU - Kim, Hannah Yejin
AU - Klintz, Senia Rosales
AU - Ködmön, Csaba
AU - Lalle, Eleonora
AU - Leo, Yee Sin
AU - Leung, Chi Chiu
AU - Märtson, Anne Grete
AU - Melazzini, Mario Giovanni
AU - Fard, Saeid Najafi
AU - Penttinen, Pasi
AU - Petrone, Linda
AU - Petruccioli, Elisa
AU - Pontali, Emanuele
AU - Saderi, Laura
AU - Santin, Miguel
AU - Spanevello, Antonio
AU - Van Crevel, Reinout
AU - Van der Werf, Marieke J.
AU - Visca, Dina
AU - Viveiros, Miguel
AU - Zellweger, Jean Pierre
AU - Zumla, Alimuddin
AU - Goletti, Delia
N1 - Funding Information:
Support statement: A. Zumla is a co-Principal Investigator of the Pan-African Network on Emerging and Re-Emerging Infections (PANDORA-IDNET) funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020 Framework Programme for Research and Innovation; and is also in receipt of a National Institutes of Health Research senior investigator award. C.W.M. Ong is funded by Singapore National Medical Research Council (NMRC/TA/0042/2015, CSAINV17nov014); National University Health System, Singapore (NUHS/RO/2017/092/SU/01, CFGFY18P11, NUHS/RO/2020/042/RO5+5/ad-hoc/1); National Centre for Infectious Diseases, Singapore (STPRG-FY19-003); and is recipient of the Young Investigator Award, Institut Merieux, Lyon, France. A-G. Märtson was funded by Marie Skłodowska-Curie Actions, grant agreement number 713660–PRONKJEWAIL–H2020-MSCA-COFUND-2015. The article is part of the activities of the Global Tuberculosis Network (GTN) and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate (ITA-80, 2017-2020-GBM/RC/LDA). Part of the work was supported by the Italian Ministry of Health, Ricerca Corrente (Linea 1 and Linea 4). Funding information for this article has been deposited with the Crossref Funder Registry.
Publisher Copyright:
©ERS 2020.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Major epidemics, including some that qualify as pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung. Tuberculosis (TB) remains the top infectious disease killer, but apart from syndemic TB/HIV little is known regarding the interaction of viral epidemics and pandemics with TB. The aim of this consensus-based document is to describe the effects of viral infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and COVID-19) and their interactions with TB. A search of the scientific literature was performed. A writing committee of international experts including the European Centre for Disease Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was established. Consensus was achieved after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process involving the core group of authors (excluding the ECDC PHE team) identified the areas requiring review/consensus, followed by a second round to refine the definitive consensus elements. The epidemiology and immunology of these viral infections and their interactions with TB are discussed with implications for diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety). This consensus document represents a rapid and comprehensive summary on what is known on the topic.
AB - Major epidemics, including some that qualify as pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung. Tuberculosis (TB) remains the top infectious disease killer, but apart from syndemic TB/HIV little is known regarding the interaction of viral epidemics and pandemics with TB. The aim of this consensus-based document is to describe the effects of viral infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and COVID-19) and their interactions with TB. A search of the scientific literature was performed. A writing committee of international experts including the European Centre for Disease Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was established. Consensus was achieved after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process involving the core group of authors (excluding the ECDC PHE team) identified the areas requiring review/consensus, followed by a second round to refine the definitive consensus elements. The epidemiology and immunology of these viral infections and their interactions with TB are discussed with implications for diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety). This consensus document represents a rapid and comprehensive summary on what is known on the topic.
UR - http://www.scopus.com/inward/record.url?scp=85090489505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090489505&partnerID=8YFLogxK
U2 - 10.1183/13993003.01727-2020
DO - 10.1183/13993003.01727-2020
M3 - Review article
C2 - 32586885
AN - SCOPUS:85090489505
SN - 0903-1936
VL - 56
JO - Scandinavian Journal of Respiratory Diseases
JF - Scandinavian Journal of Respiratory Diseases
IS - 4
M1 - 2001727
ER -